🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/07/2010 | 32,73 | 32,99 | 31,86 | 32,17 | -0,16% | 3,45% | 1.375.200 |
| 02/07/2010 | 32,45 | 32,79 | 31,92 | 32,22 | -0,25% | 2,68% | 1.084.200 |
| 01/07/2010 | 32,83 | 32,91 | 31,25 | 32,30 | -1,82% | 5,06% | 2.338.500 |
| 30/06/2010 | 33,13 | 34,10 | 32,85 | 32,90 | -0,48% | 3,77% | 1.757.700 |
| 29/06/2010 | 34,27 | 34,48 | 32,82 | 33,06 | -4,75% | 4,84% | 1.797.400 |
| 28/06/2010 | 35,16 | 35,20 | 34,23 | 34,71 | -1,00% | 2,76% | 990.400 |
| 25/06/2010 | 34,84 | 35,31 | 34,58 | 35,06 | +1,30% | 2,10% | 1.602.500 |
| 24/06/2010 | 35,01 | 35,28 | 34,50 | 34,61 | -1,87% | 2,23% | 1.342.400 |
| 23/06/2010 | 35,27 | 35,63 | 35,00 | 35,27 | -0,14% | 1,79% | 1.508.200 |
| 22/06/2010 | 36,70 | 36,92 | 35,19 | 35,32 | -3,97% | 4,71% | 2.339.000 |
| 21/06/2010 | 37,06 | 37,25 | 36,65 | 36,78 | -0,11% | 1,62% | 2.212.700 |
| 18/06/2010 | 36,72 | 36,92 | 36,32 | 36,82 | +2,99% | 1,63% | 3.401.100 |
| 17/06/2010 | 35,24 | 35,85 | 35,00 | 35,75 | +2,00% | 2,41% | 1.596.900 |
| 16/06/2010 | 34,77 | 35,17 | 34,60 | 35,05 | -0,11% | 1,64% | 2.053.700 |
| 15/06/2010 | 34,77 | 35,15 | 34,72 | 35,09 | +1,21% | 1,24% | 1.278.700 |
| 14/06/2010 | 35,14 | 35,54 | 34,61 | 34,67 | -0,97% | 2,65% | 1.064.400 |
| 11/06/2010 | 33,62 | 35,06 | 33,39 | 35,01 | +2,70% | 4,97% | 2.051.100 |
| 10/06/2010 | 32,83 | 34,09 | 32,68 | 34,09 | +4,63% | 4,29% | 1.706.700 |
| 09/06/2010 | 33,12 | 33,32 | 32,40 | 32,58 | -1,42% | 2,78% | 3.095.500 |
| 08/06/2010 | 34,01 | 34,34 | 32,68 | 33,05 | -3,14% | 4,88% | 2.167.600 |
| 07/06/2010 | 34,35 | 34,86 | 34,06 | 34,12 | -0,96% | 2,33% | 1.787.800 |
| 04/06/2010 | 34,72 | 35,24 | 34,42 | 34,45 | -3,07% | 2,36% | 2.208.000 |
| 03/06/2010 | 35,62 | 35,71 | 35,16 | 35,54 | +0,37% | 1,54% | 1.613.700 |
| 02/06/2010 | 34,14 | 35,41 | 34,01 | 35,41 | +3,57% | 4,10% | 1.988.400 |
| 01/06/2010 | 34,54 | 34,87 | 33,62 | 34,19 | -1,16% | 3,62% | 1.843.800 |
| 28/05/2010 | 34,28 | 34,76 | 33,77 | 34,59 | +0,44% | 2,89% | 2.048.700 |
| 27/05/2010 | 35,21 | 35,35 | 33,11 | 34,44 | -0,86% | 6,36% | 4.867.100 |
| 26/05/2010 | 37,72 | 37,82 | 34,64 | 34,74 | +2,33% | 8,43% | 8.918.900 |
| 25/05/2010 | 33,61 | 34,09 | 33,12 | 33,95 | -0,90% | 2,89% | 2.794.000 |
| 24/05/2010 | 34,05 | 35,20 | 34,00 | 34,26 | +0,41% | 3,52% | 2.596.600 |